Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Drug Profile

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Alternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; Iodine-131-SGMIB anti-HER2 VHH1

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Camel-IDS
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in Belgium (IV, Injection)
  • 15 Nov 2018 Camel-IDS plans a phase Ib/II trial in Breast cancer (Diagnosis)
  • 01 Jun 2018 Pharmacokinetics data from a phase I trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top